Management of 6-Mercaptopurine Related Toxicity

Initial Assessment and Monitoring

• Measure thiopurine metabolites (6-thioguanine nucleotides [6-TGN] and 6-methylmercaptopurine [6-MMP]) in patients with toxicity to guide management decisions, as recommended by the National Comprehensive Cancer Network 1, 2, 3
• Test for TPMT and NUDT15 deficiency in patients experiencing severe myelosuppression or repeated episodes of myelosuppression, as suggested by the National Comprehensive Cancer Network 4, 5

Management by Toxicity Type

Myelosuppression

• If ANC <2×10⁹/L or total white cells <3.5×10⁹/L: Withhold 6-MP until counts recover above these thresholds, according to the European Crohn’s and Colitis Organisation 1
• If neutrophils <1×10⁹/L: Warn patients to present immediately if febrile for antibiotics ± G-CSF, as recommended by the European Crohn’s and Colitis Organisation 1
• If high 6-TGN levels: Restart at lower dose once counts normalize and monitor hematology and metabolites closely, as suggested by the European Crohn’s and Colitis Organisation 1
• If high 6-MMP levels: Consider restarting low-dose 6-MP (25-33% of standard dose) with allopurinol 100 mg, according to the European Crohn’s and Colitis Organisation 1
• If TGN low or normal with myelotoxicity: Toxicity likely to recur; stop thiopurine and switch to alternative therapy, as recommended by the European Crohn’s and Colitis Organisation 1

Pancreatitis

• Do not rechallenge with 6-MP or azathioprine, even at low doses—there is a high chance of recurrence, as suggested by the European Crohn’s and Colitis Organisation 1
• Switch to alternative immunosuppressive therapy, according to the European Crohn’s and Colitis Organisation 1

Common Pitfalls to Avoid

• Do not stop 6-MP abruptly without medical advice in IBD patients, as this risks disease flare requiring steroids or hospitalization, as warned by the American Gastroenterological Association 6, 7
• Do not restart 6-MP at full dose after toxicity without considering dose reduction or allopurinol co-administration, as recommended by the European Crohn’s and Colitis Organisation 1
• Do not assume compliance issues without checking metabolite levels—lack of myelosuppression with dose escalation may indicate non-compliance, but quantification of metabolites distinguishes this from hypermetabolism, as suggested by the National Comprehensive Cancer Network 4, 5